{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Duarte Romero BL"],"funding":["National Health and Medical Research Council"],"pagination":["357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12845487"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(2)"],"pubmed_abstract":["<b>Background/Objectives</b>: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. <b>Methods</b>: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D<sub>3</sub>, conducted in Australians aged 60-84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceut"],"journal":["Nutrients"],"pubmed_title":["Effect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults-Results from the Randomized Controlled D-Health Trial."],"pmcid":["PMC12845487"],"funding_grant_id":["GNT1060183","GNT1155413","GNT1173346","GNT1120682","GNT1197958","GNT1046681"],"pubmed_authors":["English DR","Na R","McLeod DSA","Hartel G","Pham H","Webb PM","Neale RE","Whiteman DC","Baxter C","Venn AJ","Kimlin MG","Ross T","Duarte Romero BL","van der Pols JC","Waterhouse M","Ebeling PR","Armstrong BK"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Vitamin D Supplementation on Cardiometabolic Outcomes in Older Australian Adults-Results from the Randomized Controlled D-Health Trial.","description":"<b>Background/Objectives</b>: Observational studies have found inverse associations between 25-hydroxyvitamin D concentration and risk of hypertension, hypercholesterolemia and type 2 diabetes (T2D). More robust evidence from large-scale randomized controlled trials, however, is limited or inconclusive. <b>Methods</b>: The D-Health Trial (N = 21,315) is a randomized, double-blind, placebo-controlled trial of supplementation with monthly doses of 60,000 international units of oral vitamin D<sub>3</sub>, conducted in Australians aged 60-84 years. Commencing treatment with anti-hypertensive, lipid-modifying, or anti-diabetic drugs was used as a surrogate for incident hypertension, hypercholesterolemia, and T2D, respectively. Outcomes were ascertained via linkage with the Australian Pharmaceut","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-13T03:26:19.321Z","creation":"2026-06-13T03:12:48.721Z"},"accession":"S-EPMC12845487","cross_references":{"pubmed":["41599971"],"doi":["10.3390/nu18020357"]}}